Decision analysis and cost-effectiveness analysis for comparative effectiveness research-a primer

Seminars in Radiation Oncology

Volumn 24, Issue 1, 2014, Pages 14-24

  Sher, David J ^a   Punglia, Rinaa S ^b  

^a RUSH UNIVERSITY MEDICAL CENTER   (United States)

^b BRIGHAM AND WOMEN S HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; ANTINEOPLASTIC AGENT; PROSTATE SPECIFIC ANTIGEN;

ARTICLE; BONE METASTASIS; BONE PAIN; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PAIN; CANCER PALLIATIVE THERAPY; CANCER RADIOTHERAPY; CANCER RECURRENCE; CANCER SCREENING; COHORT ANALYSIS; COMPARATIVE EFFECTIVENESS; COST BENEFIT ANALYSIS; COST EFFECTIVENESS ANALYSIS; COST MINIMIZATION ANALYSIS; COST UTILITY ANALYSIS; DATA ANALYSIS; DECISION TREE; DIAGNOSTIC ERROR; DISTANT METASTASIS; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; HEALTH CARE COST; HUMAN; INCREMENTAL COST EFFECTIVENESS RATIO; INTENSITY MODULATED RADIATION THERAPY; LIFE EXPECTANCY; MASTECTOMY; MATHEMATICAL MODEL; MEDICAL DECISION MAKING; MEDICARE; METHODOLOGY; MONTE CARLO METHOD; OUTCOME ASSESSMENT; PARTIAL MASTECTOMY; PATIENT DECISION MAKING; PATIENT PREFERENCE; PRIORITY JOURNAL; PROBABILITY; PROSTATE CANCER; PROTON THERAPY; QUALITY ADJUSTED LIFE YEAR; QUALITY OF LIFE; RADIATION DOSE FRACTIONATION; RADIATION HAZARD; RANDOMIZED CONTROLLED TRIAL (TOPIC); REIMBURSEMENT; STEREOTACTIC BODY RADIATION THERAPY; TREATMENT OUTCOME; WILLINGNESS TO PAY;

COMPARATIVE EFFECTIVENESS RESEARCH; COST-BENEFIT ANALYSIS; DECISION SUPPORT TECHNIQUES; HUMANS; NEOPLASMS; RESEARCH DESIGN;

EID: 84888858548     PISSN: 10534296     EISSN: 15329461     Source Type: Journal    
DOI: 10.1016/j.semradonc.2013.08.002     Document Type: Article

References (26)

1. Meyer A.M., Carpenter W.R., Abernethy A.P., et al. Data for cancer comparative effectiveness research: past, present, and future potential. Cancer 2012, 118(21):5186-5197.
2. Spiro T., Lee E.O., Emanuel E.J. Price and utilization: Why we must target both to curb health care costs. Ann Intern Med 2012, 157:586-590.
3. Meropol N.J., Schrag D., Smith T.J., et al. American Society of Clinical Oncology guidance statement: The cost of cancer care. J Clin Oncol 2009, 27:3868-3874.
4. Mariotto A.B., Yabroff K.R., Shao Y., et al. Projections of the cost of cancer care in the United States: 2010-2020. J Natl Cancer Inst 2011, 103:117-128.
5. Shen XAP, Levin D, Rao VM, et al: Trends in radiation oncology services in the IMRT era: Evolving patterns of usage and payments in Medicare patients from 2000-2009. Int J Radiat Oncol Biol Phys 2011 [Abstract].
6. Schrag D., Kuntz K.M., Garber J.E., et al. Decision analysis-Effects of prophylactic mastectomy and oophorectomy on life expectancy among women with BRCA1 or BRCA2 mutations. N Engl J Med 1997, 336:1465-1471.
7. Elkin E.B., Weinstein M.C., Winer E.P., et al. HER-2 testing and trastuzumab therapy for metastatic breast cancer: A cost-effectiveness analysis. J Clin Oncol 2004, 22:854-863.
8. Hillner B.E., Smith T.J. Efficacy and cost effectiveness of adjuvant chemotherapy in women with node-negative breast cancer. A decision-analysis model. N Engl J Med 1991, 324:160-168.
9. Stiggelbout A.M., de Haes J.C. Patient preference for cancer therapy: An overview of measurement approaches. J Clin Oncol 2001, 19:220-230.
10. Weinstein M.C., Stason W.B. Foundations of cost-effectiveness analysis for health and medical practices. N Engl J Med 1977, 296:716-721.
11. Beck J.R., Pauker S.G. The Markov process in medical prognosis. Med Decis Making 1983, 3:419-458.
12. Sonnenberg F.A., Beck J.R. Markov models in medical decision making: A practical guide. Med Decis Making 1993, 13:322-338.
13. Heijnsdijk E.A., Wever E.M., Auvinen A., et al. Quality-of-life effects of prostate-specific antigen screening. N Engl J Med 2012, 367:595-605.
14. Barr D.A. Bending the Medicare cost curve for physicians' services: Lessons learned from Canada. J Gen Intern Med 2012, 27:1555-1559.
15. Cigna Medical Coverage Policy. Proton Beam Therapy for Prostate Cancer.
16. Hunink M.G.M. Decision Making in Health and Medicine: Integrating Evidence and Values 2001, Cambridge University Press, Cambridge.
17. Gold MR, Siegel JE, Russell LB, et al: Cost-Effectiveness in Health and Medicine. Oxford, USA, Oxford University Press, 1996, pp 1 [online resource 450 p.].
18. Drummond M.F., McGuire A. Economic Evaluation in Health Care: Merging Theory With Practice 2001, Oxford University Press, Oxford.
19. McCabe C., Claxton K., Culyer A.J. The NICE cost-effectiveness threshold: What it is and what that means. Pharmacoeconomics 2008, 26:733-744.
20. Winkelmayer W.C., Weinstein M.C., Mittleman M.A., et al. Health economic evaluations: The special case of end-stage renal disease treatment. Med Decis Making 2002, 22:417-430.
21. Konski A., Speier W., Hanlon A., et al. Is proton beam therapy cost effective in the treatment of adenocarcinoma of the prostate?. J Clin Oncol 2007, 25:3603-3608.
22. Hayman J.A., Lash K.A., Tao M.L., et al. A comparison of two methods for estimating the technical costs of external beam radiation therapy. Int J Radiat Oncol Biol Phys 2000, 47:461-467.
23. Sher D.J. Cost-effectiveness studies in radiation therapy. Expert Rev Pharmacoecon Outcomes Res 2010, 10:567-582.
24. Konski A. Radiotherapy is a cost-effective palliative treatment for patients with bone metastasis from prostate cancer. Int J Radiat Oncol Biol Phys 2004, 60:1373-1378.
25. Steenland E., Leer J.W., van Houwelingen H., et al. The effect of a single fraction compared to multiple fractions on painful bone metastases: A global analysis of the Dutch Bone Metastasis Study. Radiother Oncol 1999, 52:101-109.
26. van den Hout W.B., van der Linden Y.M., Steenland E., et al. Single- versus multiple-fraction radiotherapy in patients with painful bone metastases: Cost-utility analysis based on a randomized trial. J Natl Cancer Inst 2003, 95:222-229.